CD274 and neoplasm: In the current analysis, after 29 months of minimum follow‐up, nivolumab plus chemotherapy and nivolumab plus ipilimumab both continued to demonstrate clinically meaningful survival benefit versus chemotherapy in patients with tumor cell PD‐L1 expression ≥1% and patients in the overall population.